Biochemical markers of myocyte injury in heart failure

Heart

Volumn 90, Issue 10, 2004, Pages 1110-1113

  Sato, Y ^a   Kita, T ^a   Takatsu, Y ^b   Kimura, T ^a  

^a KYOTO UNIVERSITY   (Japan)

^b Hyogo Prefectural Amagasaki Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTATE AMINOTRANSFERASE; BIOCHEMICAL MARKER; BRAIN NATRIURETIC PEPTIDE; CREATINE KINASE; CREATINE KINASE MB; FATTY ACID BINDING PROTEIN; LACTATE DEHYDROGENASE; MYOGLOBIN; MYOSIN LIGHT CHAIN; TROPONIN I; TROPONIN T;

CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; DISEASE MARKER; DISEASE SEVERITY; HEART FUNCTION; HEART INJURY; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HUMAN; IMMUNOASSAY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SURVIVAL RATE;

BIOLOGICAL MARKERS; CARRIER PROTEINS; FATTY ACID-BINDING PROTEINS; HEART FAILURE, CONGESTIVE; HUMANS; MYOCYTES, CARDIAC; MYOSIN LIGHT CHAINS; PROGNOSIS; TROPONIN I; TROPONIN T;

EID: 4644230111     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2003.023895     Document Type: Review

References (49)

1. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. J Heart Lung Transplant 2002;21:189-203.
2. Remme WJ, Swedberg K. Task force for the diagnosis and treatment of chronic heart failure, European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001;22:1527-60.
3. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling - concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. On behalf of an international forum on cardiac remodeling. J Am Coll Cardiol 2000;35:569-82.
4. St John Sutton MG, Sharpe N. Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation 2000;101:2981-8.
5. Crowley LV. Creatine phosphokinase activity in myocardial infarction, heart failure, and following various diagnostic and therapeutic procedures. Clin Chem 1968;14:1185-96.
6. Chemnitz G, Schmidt E, Schmidt FW, et al. Determination of creatine kinase and CK-MB in heart failure. Med Klin 1978;73:1809-11.
7. Christenson RH, Azzazy HM. Biochemical markers of the acute coronary syndromes. Clin Chem 1998;44:1855-64.
8. Bodor GS, Survant L, Voss EM, et al. Cardiac troponin T composition in normal and regenerating human skeletal muscle. Clin Chem 1997;43:476-84.
9. Bhayana V, Gongoulias T, Cohoe S, et al. Discordance between results for serum troponin T and troponin I in renal disease. Clin Chem 1995;41:312-7.
10. Baum H, Braun S, Gerhardt W, et al. Multicenter evaluation of a second-generation assay for cardiac troponin T. Clin Chem 1997;43:1877-84.
11. Ricchiuti V, Voss EM, Ney A, et al. Cardiac troponin T isoforms expressed in renal diseased skeletal muscle will not cause false-positive results by the second generation cardiac troponin T assay by Boehringer Mannheim. Clin Chem 1998;44:1919-24.
12. Bodor GS, Porterfield D, Voss EM, et al. Cardiac troponin I is not expressed in fetal and healthy or diseased adult human skeletal muscle tissue. Clin Chem 1995;41:1710-5.
13. Katus HA, Remppis A, Neumann FJ, et al. Diagnostic efficiency of troponin T measurements in acute myocardial infarction. Circulation 1991;83:902-12.
14. Adams JE 3rd, Schechtman KB, Landt Y, et al. omparable detection of acute myocardial infarction by creatine kinase MB isoenzyme and cardiac troponin I. Clin Chem 1994;40:1291-5.
15. Alpert JS, Thygesen K, Antman E, et al. Myocardial infarction redefined-a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000;36:959-69.
16. Jaffe AS, Ravkilde J, Roberts R, et al. It's time for a change to a tropanin standard. Circulation 2000;102:1216-20.
17. Piper HM, Schwarz P, Spahr R, et al. Early enzyme release from myocardial cells is not due ta irreversible cell damage. J Mol Cell Cardiol 1984;16:385-8.
18. Katus HA, Remppis A, Scheffold T, et al. Intracellular compartmentation of cardiac troponin T and its release kinetics in patients with reperfused and nonreperfused myocardial infarction. Am J Cardiol 1991;67:1360-7.
19. Schaap FG, Van der Vusse GJ, Glatz JF. Fatty acid-binding proteins in the heart. Mol Cell Biochem 1998;180:43-51.
20. Glatz JF, Van Bilsen M, Paulussen RJ, et al. Release of fatty acid-binding protein from isolated rat heart subjected to ischemia and reperfusion or to the calcium paradox. Biochem Biophys Acta 1988;961:148-52.
21. Ishii J, Wang J, Naruse H, et al. Serum concentrations of myoglobin vs human heart-type cytoplasmic fatty acid-binding protein in early detection of acute myocardial infarction. Clin Chem 1997;43:1372-8.
22. Isobe M, Nagai R, Ueda S, et al. Quantitative relationship between left ventricular function and serum cardiac myosin light chain I level after coronary reperfusion in patients with acute myocardial infarction. Circulation 1987;76:1251-61.
23. Matsumori A, Kawai C, Yamada T, et al. Mechanism and significance of myocardial uptake of antimyosin antibody in myocarditis and cardiomyopathy: clinical and experimental studies. Clin Immunol Immunopathol 1993;68:215-9.
24. Sato Y, Kataoka K, Matsumori A, et al. Measuring serum aminoterminal type III procollagen peptide, 7S domain of type IV collagen, and cardiac troponin T in patients with idiopathic dilated cardiomyopathy and secondary cardiomyopathy. Heart 1997;78:505-8.
25. Sato Y, Yamada T, Taniguchi R, et al. Persistently increased serum concentrations of cardiac troponin T in patients with idiopathic dilated cardiomyopathy are predictive of adverse outcomes. Circulation 2001;103:369-74.
26. European Study Group on Diastolic Heart Failure. How to diagnose diastolic heart failure. Eur Heart J 1998;19:990-1003.
27. Sato Y, Taniguchi R, Nagai K, et al. Measurements of cardiac troponin T in patients with hypertrophic cardiomyopathy. Heart 2003;89:659-60.
28. Dispenzieri A, Kyle RA, Gertz MA, et al. Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins. Lancet 2003;361:1787-9.
29. Sato Y, Taniguchi R, Makiyama T, et al. Measurements of serum cardiac troponin T and plasma brain natriuretic peptide in patients with severe cardiac decompensation. Heart 2002;88:647-8.
30. Setsuta K, Seino Y, Takahashi N, et al. Clinical significance of elevated levels of cardiac troponin T in patients with chronic heart failure. Am J Cardiol 1999;84:608-11.
31. Sato Y, Taniguchi R, Yamada T, et al. Measurements af serum cardiac troponin T in patients with heart failure. Am Heart J 2003;145:e18.
32. Donnelly R, Millar-Craig MW. Cardiac troponins: IT upgrade for the heart. Lancet 1998;351:537-9.
33. Coudrey L. The troponins. Arch Intern Med 1998;158:1173-80.
34. Tornos MP, Olona M, Permanyer-Miralda G, et al. Heart failure after valve replacement for aortic regurgitation: prospective 20-year study. Am Heart J 1998;136:681-7.
35. Ishii J, Nomura M, Nakamura Y, et al. Risk stratification using a combination of cardiac troponin T and brain natriuretic peptide in patients hospitalized for worsening chronic heart failure. Am J Cardiol 2002;89:691-5.
36. Missov E, Calzolari C. Elevated cardiac troponin I in some patients with severe congestive heart failure [abstract]. J Mol Cell Cardiol 1995;27:A-405.
37. Missov E, Calzolari C, Pau B. Circulating cardiac troponin I in severe congestive heart failure. Circulation 1997;96:2953-8.
38. Cardinale D, Sandri MT, Martinoni A, et al. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol 2000;36:517-22.
39. Schulz O, Kromer A. Cardiac troponin I: a potential marker of exercise intolerance in patients with moderate heart failure. Am Heart J 2002;144:351-8.
40. Horwich TB, Patel J, MacLellan WR, et al. Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure. Circulation 2003;108:833-8.
41. Setsuto K, Seino Y, Ogawa T, et al. Use of cytosolic and myofibril markers in the detection of ongoing myocardial damage in patients with chronic heart failure. Am J Med 2002;113:717-22.
42. Hansen MS, Stanton EB, Gawad Y, et al. Canadian PROFILE investigators. Relation of circulating cardiac myosin light chain 1 isoform in stable severe congestive heart failure to survival and treatment with flosequinan. Am J Cardiol 2002;90:969-73.
43. McDonagh TA, Robb SD, Murdoch DR, et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet 1998;351:9-13.
44. Troughton RW, Frampton CM, Yandle TG, et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000;355:1126-30.
45. Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet 2003;362:316-22.
46. Mann DL. Mechanisms and models in heart failure. A combinatorial approach. Circulation 1999;100:999-1008.
47. Baig MK, Mahon N, McKenna WJ, et al. The pathophysiology of advanced heart failure. Am Heart J 1998;135:S216-30.
48. McMurray J, Pfeffer MA. New therapeutic options in congestive heart failure: part I. Circulation 2002;105:2099-106.
49. Anand IS, Florea VG, Fisher L. Surrogate end points in heart failure. J Am Coll Cardiol 2002;39:1414-21.